Cytokine biomarkers as biomarkers predictive of the clinical response for glatiramer acetate

摘要

A procedure for predicting the degree of clinical response to treatment with glatiramer acetate in a human subject suffering from multiple sclerosis or a single clinical attack consistent with multiple sclerosis, the method comprising assessing the concentration of IL-17 in the supernatant of the CMSP from of the subject's blood, and identify the human subject as a patient responding to glatiramer acetate based on the concentration of IL-17, this subject being identified as a patient responding to glatiramer acetate through the steps comprising, (i) purify the CMSP from the subject's blood and then cryopreserve the CMSP; (ii) thaw and then cultivate cryopreserved CMSPs overnight in culture medium enriched with 5% human serum; (iii) stimulate 40,000 of said CMSPs grown with 1 mg / ml of PMA and 5 mg / ml of ionomycin in a final volume of 200 microliters for 6 hours; and (v) identify the human subject as a patient responding to glatiramer acetate if the IL-17 concentration of the CMSP supernatant after step (iii) is greater than or equal to 120 pg / ml,